HELLP Syndrome and the Effects on the Neonate

Neonatal Network : NN
|January 24, 2016
PubMed

Insights

HELLP syndrome, a serious pregnancy complication, can affect newborns significantly. Early recognition of risks aids clinicians in preparing for delivery, reducing infant mortality and morbidity.

Area of Science:

  • Obstetrics and Gynecology
  • Neonatal Medicine
  • Perinatal Health

Background:

  • HELLP syndrome (Hemolysis, Elevated Liver enzymes, and Low Platelets) is a severe condition complicating pregnancy.
  • Diagnosis typically occurs between 27 and 37 weeks gestation, but can also manifest postpartum.
  • Adverse neonatal outcomes associated with HELLP syndrome necessitate focused clinical attention.

Purpose of the Study:

  • To highlight the significant effects of HELLP syndrome on neonates.
  • To emphasize the importance of recognizing neonatal risks associated with HELLP syndrome.
  • To underscore how preparation for neonates can mitigate adverse outcomes.

Main Methods:

  • This study synthesizes existing knowledge on HELLP syndrome and its neonatal impact.
  • Clinical observations and literature review form the basis of the findings.
  • Focus is on the implications for neonatal care and management.

Main Results:

  • HELLP syndrome poses considerable risks to neonates, including potential complications.
  • Timely identification of these risks is crucial for effective neonatal management.
  • The timing of diagnosis, whether antepartum or postpartum, influences neonatal care strategies.

Conclusions:

  • Recognizing the potential impact of HELLP syndrome on neonates is critical for obstetric and neonatal care providers.
  • Proactive preparation for affected neonates can significantly reduce mortality and morbidity rates.
  • Improved understanding and management strategies are essential for optimizing neonatal outcomes in cases of HELLP syndrome.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the...
47.2K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
328
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
2.0K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
697